SPECTRUM PHARMACEUTICALS AKTIE | Aktienkurs | Nachrichten | Kurs

DAX	6.693	-1,4%	Dow	12.801	-0,7%	Euro	1,3200	-0,7%
ESt50	2.481	-1,7%	Nas	2.904	-0,8%	Öl	117,6	-0,9%
TDax	769,9	-0,4%	Nikkei	8.947	-0,6%	Gold	1.721	-0,5%

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Depot
Times + Sales	Chart-Analyse	Analysen	Dividende/HV	Profil	Optionsscheine	Watchlist
Börsenplätze	Chartvergleich	Kursziele		Insidertrades	Knock-outs	myfinanzen
Orderbuch	Realtime Stuttgart	RSS Feed		im Forum	Fonds	Senden/Drucken
Historisch	Realtime Push			IR-Daten	Anleihen	handeln

Relevant
Alle
vom Unternehmen

Sprache:
Alle
DE
EN

Sortieren:
Datum
meistgelesen

02.12.11	Spectrum Pharmaceuticals Gets Lift from FDA Action On One Of Its Cancer Treatments (EN, Forbes)
22.11.11	Trend-Aktien Fehlanzeige? - 3 US-Kursraketen im Check! - Teil 2 (finanzen.net)
23.09.11	Does Spectrum Pharmaceuticals Have a Bright Future? (EN, Benzinga earnings)
30.06.11	Hearing Chatter that Globes Believes Spectrum Pharmaceuticals Could be Takeover Target (EN, Benzinga rumors)
16.06.11	Which Path Will Spectrum Pharmaceuticals Take? (EN, MotleyFool)
02.05.11	Spectrum Pharmaceuticals erhält Zulassungserweiterung für Fusilev, Aktie deutlich fester (Aktiencheck)

07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
04.01.12	Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference (Businesswire)
12.12.11	Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications (Businesswire)
12.12.11	Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement (Businesswire)

07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
04.01.12	Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference (Businesswire)
12.12.11	Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications (Businesswire)
12.12.11	Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement (Businesswire)

22.11.11	Trend-Aktien Fehlanzeige? - 3 US-Kursraketen im Check! - Teil 2 (finanzen.net)
02.05.11	Spectrum Pharmaceuticals erhält Zulassungserweiterung für Fusilev, Aktie deutlich fester (Aktiencheck)

02.12.11	Spectrum Pharmaceuticals Gets Lift from FDA Action On One Of Its Cancer Treatments (EN, Forbes)
23.09.11	Does Spectrum Pharmaceuticals Have a Bright Future? (EN, Benzinga earnings)
30.06.11	Hearing Chatter that Globes Believes Spectrum Pharmaceuticals Could be Takeover Target (EN, Benzinga rumors)
16.06.11	Which Path Will Spectrum Pharmaceuticals Take? (EN, MotleyFool)

22.11.11	Trend-Aktien Fehlanzeige? - 3 US-Kursraketen im Check! - Teil 2 (finanzen.net)
02.05.11	Spectrum Pharmaceuticals erhält Zulassungserweiterung für Fusilev, Aktie deutlich fester (Aktiencheck)

07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
04.01.12	Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference (Businesswire)
12.12.11	Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications (Businesswire)
12.12.11	Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement (Businesswire)

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
04.01.12	Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference (Businesswire)
12.12.11	Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications (Businesswire)
12.12.11	Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)

23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER?, the Journal of the American Cancer Society (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen
Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen
vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Kurszeit	09:00:18	Kursdatum	10.02.2012
Tageshoch	9,96	Eröffnung	9,96
Tagestief	9,96	Vortag	10,27
52 W. Hoch	12,50	Volumen (Stück)	n/a
52 W. Tief	4,60	Marktkapitalisierung (EUR)	582,85 Mio.
52 W. Performance		Börse	FSE

Kurszeit	22:00:00	Kursdatum	10.02.2012
Tageshoch	14,19	Eröffnung	13,52
Tagestief	13,52	Vortag	13,48
52 W. Hoch	15,99	Volumen (Stück)	441.081
52 W. Tief	6,42	Marktkapitalisierung (USD)	808,87 Mio.
52 W. Performance		Börse	NAS

25.03.11	Spectrum Pharmaceuticals outperform	RBC Capital Markets
14.10.09	Spectrum Pharmaceuticals market outperform	Rodman & Renshaw, LLC
20.08.08	Spectrum Pharmaceuticals chancenreich	Der Aktionär
24.04.08	Spectrum Pharmaceuticals Downgrade	Oppenheimer & Co. Inc.
19.03.08	Spectrum Pharmaceuticals Downgrade	Brean Murray, Carret & Co., LLC

25.03.11	Spectrum Pharmaceuticals outperform	RBC Capital Markets
14.10.09	Spectrum Pharmaceuticals market outperform	Rodman & Renshaw, LLC
20.08.08	Spectrum Pharmaceuticals chancenreich	Der Aktionär
14.11.07	Spectrum Pharmaceuticals Position aufbauen	Biotech-Report
10.10.07	Spectrum Pharmaceuticals buy	Brean Murray, Carret & Co., LLC

24.04.08	Spectrum Pharmaceuticals Downgrade	Oppenheimer & Co. Inc.
19.03.08	Spectrum Pharmaceuticals Downgrade	Brean Murray, Carret & Co., LLC
26.07.07	Spectrum Pharmaceuticals Downgrade	Friedman, Billings Ramsey & Co

Finanzen.net

Spectrum Pharmaceuticals Aktie [WKN: 164623 / ISIN: US84763A1088]

Realtimekurs Spectrum Pharmaceuticals IncShs in Euro

Aktienkurs Spectrum Pharmaceuticals IncShs in EUR

Aktienkurs Spectrum Pharmaceuticals IncShs in USD

Nachrichten zu Spectrum Pharmaceuticals IncShs

Analysen zu Spectrum Pharmaceuticals IncShs

Profil Spectrum Pharmaceuticals IncShs

Spectrum Pharmaceuticals CHART - 1 Jahr - FSE

ANZEIGE

Spectrum Pharmaceuticals Kennzahlen

Spectrum Pharmaceuticals Historische Kurse

Zur Aktie Spectrum Pharmaceuticals

Zum Unternehmen Spectrum Pharmaceuticals

Aktien gleicher Branche mit besserer 1J Perf.

Passende Fonds

Marktkapitalisierung in Mio. EUR	582,85
Anzahl Aktien in Mio.	57,41

10.02.2012	9,96
09.02.2012	10,27
08.02.2012	10,37
07.02.2012	10,81	2.000
06.02.2012	10,77	20

getgoods	+795,5%
Mania Technologie	+456,3%
emQtec	+375,0%
CPU Softwarehouse	+363,3%
Windhoff	+354,5%

WKN	164623
ISIN	US84763A1088